Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	SUVN-G3031 2mg	63
Overall Study	STARTED	SUVN-G3031 4mg	64
Overall Study	STARTED	Placebo	63
Overall Study	Safety Population	SUVN-G3031 2mg	63
Overall Study	Safety Population	SUVN-G3031 4mg	63
Overall Study	Safety Population	Placebo	62
Overall Study	Intent-to-treat (ITT) Population	SUVN-G3031 2mg	54
Overall Study	Intent-to-treat (ITT) Population	SUVN-G3031 4mg	53
Overall Study	Intent-to-treat (ITT) Population	Placebo	57
Overall Study	COMPLETED	SUVN-G3031 2mg	51
Overall Study	COMPLETED	SUVN-G3031 4mg	50
Overall Study	COMPLETED	Placebo	53
Overall Study	NOT COMPLETED	SUVN-G3031 2mg	12
Overall Study	NOT COMPLETED	SUVN-G3031 4mg	14
Overall Study	NOT COMPLETED	Placebo	10

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04072380/flow